Spectral AI, Inc. announced that it has added two new U.S. Clinical Trial Sites for its 2024 Burn Pivotal Study: the University of California San Diego and the University of Utah. These new locations expand the total number of U.S. Clinical Trial sites to 14. The 2024 U.S. Burn Pivotal Study is designed to validate the AI-driven algorithm used by Spectral AI's DeepView System for burn indication.

The study is scheduled to be completed in the fourth quarter of 2024 and it is expected to be the final clinical trial before the Company seeks FDA approval of its DeepView System for burn indication in 2025.